OverviewChartNewsTraderScreen

Soc. Generale Knock-Out AZN/  DE000SD9JQM7  /

Frankfurt Zert./SG
9/2/2024  12:23:02 PM Chg.0.000 Bid1:12:28 PM Ask1:12:28 PM Underlying Strike price Expiration date Option type
7.110EUR 0.00% 7.120
Bid Size: 10,000		 7.130
Ask Size: 10,000		 Astrazeneca PLC ORD ... 72.871 GBP 12/31/2078 Call
GlobeNewswire 8/12 Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune...
GlobeNewswire 8/8 Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets...
GlobeNewswire 8/6 Cellectis Provides Financial Results for the Second Quarter 2024
GlobeNewswire 8/6 FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
TeleTrader 7/25 AstraZeneca's Q2 revenue up by 13% to $12.94B
GlobeNewswire 7/15 AstraZeneca Closes Acquisition of Amolyt Pharma
GlobeNewswire 6/26 As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire 6/18 Mika Health Collaborates with AstraZeneca and Daiichi Sankyo to Deliver AI-Enabled Mobile Support to...
GlobeNewswire 6/18 Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire 6/13 Rheumatologists' Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
GlobeNewswire 5/28 Cellectis Reports Financial Results for First Quarter 2024
TeleTrader 5/21 AstraZeneca to deliver $80B total revenue by 2030
TeleTrader 5/20 AstraZeneca to build $1.5B plant in Singapore
GlobeNewswire 5/8 Annual NMDP Gala in New York Raises More Than $560,000, Enabling More Patients to Receive Life-Savin...
GlobeNewswire 5/6 FibroGen Reports First Quarter 2024 Financial Results
GlobeNewswire 5/6 Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
GlobeNewswire 5/2 Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...
GlobeNewswire 4/29 Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
TeleTrader 4/25 Europe opens mostly down after corporate earnings
TeleTrader 4/25 AstraZeneca Q1 revenue jumps 19% to $12.7B
GlobeNewswire 3/28 HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Pati...
TeleTrader 3/19 AstraZeneca to acquire Fusion for $2 billion
GlobeNewswire 3/18 AAFA Statement in Response to AstraZeneca Asthma Inhaler Cost Announcement
TeleTrader 3/14 AstraZeneca to acquire Amolyt Pharma for $1.05B
GlobeNewswire 3/14 Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca